VIVA 2019: Revolutions system meets primary and safety endpoints in REVEAL study
Findings from the REVEAL study confirm a favourable safety and effectiveness profile through six months for the Revolution peripheral atherectomy system from Rex Medical....
VIVA 2019: One-year freedom from clinically-driven target lesion revascularisation in MIMICS-3D registry
One-year results of the MIMICS-3D study were announced today at the 2019 Vascular Interventional Advances conference (VIVA; 4–7 November, Las Vegas, USA). Freedom from...
VIVA 2019: Temporary Spur stent system appears to be feasible and safe method for...
Today at the 2019 Vascular Interventional Advances conference (VIVA; 4–7 November, Las Vegas, USA), Thomas Zeller (Bad Krozingen, Germany) gave an update on the...
VIVA 2019: TOBA II BTK meets primary safety and efficacy endpoints through six months
It was announced today at the 2019 Vascular Interventional Advances conference (VIVA) (4–7 November, Las Vegas, USA) that, through six months, TOBA II BTK...
